Table 1.
The demographic and clinical characteristics of population in study.
| Variable | Entire cohort | TOC | ABA | Differences between TOC vs. ABA |
|---|---|---|---|---|
| (18 patients) | (8 patients, 44.4%) | (10 patients, 55.6%) | P | |
| Gender, n of female (%) | 14 F/18 (77.8%) | 6 F/8 (75%) | 8F/10 (80%) | NS |
| Age at onset months [median (range)] | 29 | 30 | 29 | NS |
| (12–105) | (12–105) | (20–83) | ||
| Disease [n (%)] | ||||
| JIA-U | 15 (83.3%) | 6 (75%) | 9 (90%) | NS |
| Behçet | 1 (5.6%) | 1 (12.5%) | 0 | |
| Idiopathic | 2 (11.1%) | 1 (12.5%) | 1 (10%) | |
| Presence of comorbidity [n (%)] | 2 | 1 | 1 | NS |
| (11.1%) | (12.5%) | (10%) | ||
| ANA positivity [n (%)] | 15 (83.3%) | 6 (75%) | 9 (90%) | NS |
| ANCA positivity [n (%)] (data in 12/18) | 4 (22.2%) | 2 (25%) | 2 (20%) | NS |
| HLA B51 | 1 (5.6%) | 1 (12.5%) | 0 | NS |
| ESR mm/h (median) | 41 (4–92) | 35.5 (21.4) | 48.2 (SD 25.2) | NS |
| CRP mg/dl (median) | 0 (0) | 1 (SD 0) | 1 (SD 0) | NS |
| Laterality of uveitis | 6 (75%) | 5 (50%) | NS | |
| Bilateral [n (%)] | 11 (61.1%) | |||
| Anatomical location of uveitis | ||||
| Anterior | 16 (88.9%) | 7 (87.5%) | 9 (90%) | NS |
| Intermediate | 0 | NS | ||
| Posterior | 2 (11.1%) | 1 (12.5%) | 1 (10%) | |
| Panuveitis | 0 | |||
| Previous treatments | ||||
| MTX [n (%)] | 18 (100%) | 8 (100%) | 10 (100%) | NS |
| ETA [n (%)] | 4 (22.2%) | 2 (25%) | 2 (20%) | NS |
| ADA [n (%)] | 18 (100%) | 8 (100%) | 10 (100%) | NS |
| IFX [n (%)] | 1 (5.6%) | – | 1 (10%) | NS |
| GOL [n (%)] | 1 (5.6%) | 1 (12.5%) | – | NS |
| CAN [n (%)] | 1 (5.6%) | 1 (12.5%) | – | NS |
| ABA [n (%)] | 3 (16.7%) | 3 (37.5%) | – | NS |
ABA, abatacept; TOC, Tocilizumab; F, female; ANA, antinuclear antibody; ESR, erythro-sedimentation rate; CRP, C-reactive protein; NS, not significative; JIA-U, juvenile idiopathic associated uveitis; n, number; SD, standard deviation; MTX, methotrexate; ETA, etanercept; ADA, adalimumab; CAN, canakinumab; Gol, golimumab; IFX, infliximab.